Robert Steven Sikorski
Keine laufenden Positionen mehr
Karriereverlauf von Robert Steven Sikorski
Ehemalige bekannte Positionen von Robert Steven Sikorski
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2016 | 20.03.2017 |
| Corporate Officer/Principal | 20.03.2017 | 30.04.2017 | |
| Medimmune, Inc. | Corporate Officer/Principal | 01.12.2010 | 01.09.2014 |
| AMGEN INC. | Corporate Officer/Principal | 01.03.2006 | 01.12.2010 |
MedNav, Inc.
 MedNav, Inc. Packaged SoftwareTechnology Services MedNav, Inc. develops mobile health applications. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1998 | 01.01.2003 |
Ausbildung von Robert Steven Sikorski
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
| Medimmune, Inc. | Health Technology |
MedNav, Inc.
MedNav, Inc. Packaged SoftwareTechnology Services MedNav, Inc. develops mobile health applications. | Technology Services |
- Börse
- Insiders
- Robert Steven Sikorski
- Erfahrung
